TAS-102 ± Bev for Refractory mCRC
SUNLIGHT: Phase III Trial of TAS-102 With or Without Bevacizumab for Third-line Treatment of Refractory Metastatic Colorectal Cancer

Released: January 30, 2023

Expiration: January 29, 2024

Activity

Progress
1
Course Completed